본문으로 건너뛰기
← 뒤로

Unusual Skeletal Muscle Recurrence of Mantle Cell Lymphoma After Rituximab Maintenance Therapy Detected on 18 F-FDG PET/CT.

2/5 보강
Clinical nuclear medicine 2026 Vol.51(5) p. e332-e333 Lymphoma Diagnosis and Treatment
TL;DR The case of a 64-year-old woman with MCL who initially achieved complete metabolic remission following R-CHOP chemotherapy and rituximab maintenance is reported, however, restaging with 18F-FDG PET/CT revealed extensive skeletal muscle recurrence.
Retraction 확인
출처
PubMed DOI OpenAlex Semantic 마지막 보강 2026-04-28
OpenAlex 토픽 · Lymphoma Diagnosis and Treatment CNS Lymphoma Diagnosis and Treatment Sarcoma Diagnosis and Treatment

Balgi V, Kumar SA, Goyal H, Ganesan P, Halanaik D

📝 환자 설명용 한 줄

The case of a 64-year-old woman with MCL who initially achieved complete metabolic remission following R-CHOP chemotherapy and rituximab maintenance is reported, however, restaging with 18F-FDG PET/CT

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Vishnu Balgi, Srinivas Ananth Kumar, et al. (2026). Unusual Skeletal Muscle Recurrence of Mantle Cell Lymphoma After Rituximab Maintenance Therapy Detected on 18 F-FDG PET/CT.. Clinical nuclear medicine, 51(5), e332-e333. https://doi.org/10.1097/RLU.0000000000006163
MLA Vishnu Balgi, et al.. "Unusual Skeletal Muscle Recurrence of Mantle Cell Lymphoma After Rituximab Maintenance Therapy Detected on 18 F-FDG PET/CT.." Clinical nuclear medicine, vol. 51, no. 5, 2026, pp. e332-e333.
PMID 41284926

Abstract

Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin lymphoma that typically presents with lymphadenopathy and extranodal involvement, most commonly affecting the spleen and gastrointestinal tract. Skeletal muscle infiltration is exceedingly rare, particularly in MCL. We report the case of a 64-year-old woman with MCL who initially achieved complete metabolic remission following R-CHOP chemotherapy and rituximab maintenance. However, restaging with 18 F-FDG PET/CT revealed extensive skeletal muscle recurrence. This case underscores the critical role of 18 F-FDG PET/CT in identifying atypical relapse patterns in MCL and highlights the need for vigilant, long-term surveillance following therapy.

MeSH Terms

Humans; Lymphoma, Mantle-Cell; Rituximab; Female; Middle Aged; Positron Emission Tomography Computed Tomography; Fluorodeoxyglucose F18; Recurrence; Muscle, Skeletal